Claris Lifesciences Ltd.
http://www.clarislifesciences.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Claris Lifesciences Ltd.
The Baxter/Claris Warning Letter: Out Of Spec, Out Of Mind
US FDA's inspection found a major problem in the operations of the facility that became Baxter’s when it acquired Claris: staff were blaming the laboratory for out-of-specification test results when they should have been fixing the manufacturing process. The result: a warning letter packed with assignments for the new owners.
Slayback’s ‘Thoughtful’ Generics Play Nets $60m KKR Investment
Niche plays continue to attract deal interest, with the global investment firm KKR pumping in $60m in the complex generic and specialty products firm Slayback Pharma, headed by a former executive of India’s Dr Reddy’s Laboratories.
Slayback’s ‘Thoughtful’ Generics Play Nets $60m KKR Investment
Niche plays continue to attract deal interest, with the global investment firm KKR pumping in $60m in the complex generic and specialty products firm Slayback Pharma, headed by a former executive of India’s Dr Reddy’s Laboratories.
Baxter Injects $625m In ‘Foundational Asset’ Claris
Baxter has snapped up India’s Claris Injectables, accelerating efforts to become a global leader in generic injectables. The deal also puts the spotlight back on the significant M&A appetite in the niche injectables segment and the scarcity premiums that such assets can command.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice